Contact Information
Emily Wang, Ph.D.
  • Associate Professor, Cancer Biology
  • Co-leader, Molecular and Cellular Biology of Cancer

Research Areas

Professional Experience

• 2013 - present, Associate Professor, Department of Cancer Biology, City of Hope Beckman Research Institute, Duarte, CA
• 2008 - 2013, Assistant Professor, Department of Cancer Biology, City of Hope Beckman Research Institute, Duarte, CA
• 2003 - 2008, Postdoctoral Fellow / Research Assistant Professor, Vanderbilt-Ingram Cancer Center, Vanderbilt University, Nashville, TN
• 2002 - 2003, Postdoctoral Fellow, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD
• 1999 - 2002, Ph.D. Candidate, Joint Program, School of Biological Sciences, University of Nebraska-Lincoln
• 1997 - 1999, Ph.D. Candidate, Joint Program, Department of Biochemistry and Molecular Biology, Nankai University, Tianjin, China
• 1996 - 1997, Undergraduate Student / Research Associate, Department of Biochemistry and Molecular Biology, Nankai University, Tianjin, China


  • 2006 - 2008, Vanderbilt University Medical Center, Nashville, TN, Research Assistant Professor, Cancer Biology
  • 2003 - 2006, Vanderbilt University Medical Center, Nashville, TN, Postdoctoral, Cancer Biology
  • 2002 - 2003, Johns Hopkins School of Medicine, Baltimore, MD, Postdoctoral, Viral Oncology
  • 1999 - 2002, University of Nebraska-Lincoln, Lincoln, NE, Ph.D. (joint), Molecular Virology
  • 1997 - 1999, Nankai University, Tianjin, China, Ph.D., Molecular Virology
  • 1993 - 1997, Nankai University, Tianjin, China, B.S., Molecular Biology


• 2006, American Association for Cancer Research (AACR) Scholar-in-Training Award
• 2006, Vanderbilt-Ingram Cancer Center Retreat Most Outstanding Poster
• 2007, American Cancer Society-Institutional Research Grant Award (Vanderbilt)
• 2007, NIH Pathway to Independence Award (K99/R00)
• 2010, California Breast Cancer Research Program Innovative Developmental and Exploratory Award
• 2011, California Breast Cancer Research Program Innovative Developmental and Exploratory Award
• 2012, Breast Cancer Research Foundation-AACR Translational Breast Cancer Research Award
• 2012, City of Hope Women’s Cancer Program “Hope Idol” Award


  • 2005 - present, Member, AACR and AACR-Women in Cancer Research
  •  2007 - 2012, Ad Hoc Reviewer, DOD, Breast Cancer Research Program
  •  2010, Ad Hoc Reviewer, NIH/NCI, Cancer Nanotechnology Program
  •  2011 - 2013, Ad Hoc Reviewer, NIH/NCI, NCI-I Career Development Group
  •  2012 - 2013, Ad Hoc Reviewer, NIH/NCI, Tumor Progression and Metastasis Panel
  •  2013 - present, Ad Hoc Reviewer, NIH/NCI, Cancer Molecular Pathobiology Panel
  •  2013 - present, Standing Member, NIH/NCI, NCI-I Career Development Group


Fong MY, Zhou W, Liu L, Alontaga AY, Chandra M, Ashby J, Chow A, O’Connor ST, Li S, Chin AR, Somlo G, Palomares M, Li Z, Tremblay JR, Tsuyada A, Sun G, Reid MA, Wu X, Swiderski P, Ren X, Shi Y, Kong M, Zhong W, Chen Y, Wang SE*. Nat Cell Biol. 2015 Feb;17(2):183-94. Breast-cancer-secreted miR-122 reprograms glucose metabolism in premetastatic niche to promote metastasis. Highlighted in Nat Rev Cancer (2015 Mar).
Zhou W, Fong MY, Min Y, Somlo G, Liu L, Palomares MR, Yu Y, Chow A, O'Connor STF, Chin AR, Yen Y, Wang Y, Marcusson EG, Chu P, Wu J, Wu X, Li AX, Li Z, Gao H, Ren X, Boldin MP, Lin PC, Wang SE*. Cancer Cell. 2014 Apr;25(4):501-15. Cancer-secreted miR-105 destroys vascular endothelial barriers to promote metastasis. Featured Article. Highlighted in Nat Rev Genet (2014 Jun;15(6):362); Nat Rev Cancer (2014 Jun;14(6):386-7); Nat Med (2014 May;20(5):482); Sci Signal (2014 Apr;7(322):ec106);Cancer Res (2014 Jun;74(11):2905).
Chow A, Zhou W, Liu L, Fong MY, Champer J, Van Haute D, Chin AR, Ren X, Gugiu BG, Meng Z, Huang W, Ngo V, Kortylewski M, Wang SE*. Sci Rep. 2014 Jul;4:5750. doi: 10.1038/srep05750. Macrophage immunomodulation by breast cancer-derived exosomes requires Toll-like receptor 2-mediated activation of NF-B.
Liu L, Zhou W, Cheng CT, Ren X, Somlo G, Fong MY, Chin AR, Li H, Yu Y, Xu Y, O'Connor ST, O'Connor TR, Ann DK, Stark JM, Wang SE*. Mol Cancer Res. 2014 Nov;12(11):1597-609. TGF induces “BRCAness” and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes.
Ashby J, Flack K, Jimenez LA, Duan Y, Khatib AK, Somlo G, Wang SE, Cui X, Zhong W. Anal Chem. 2014 Sep;86(18):9343-9. Distribution profiling of circulating microRNAs in serum.
Tsuyada A, Chow A, Wu J, Somlo G, Chu P, Loera S, Luu T, Li AX, Wu X, Ye W, Chen S, Zhou W, Yu Y, Wang YZ, Ren X, Li H, Scherle P, Kuroki Y, Wang SE*. Cancer Res. 2012 Jun;72(11):2768-79. CCL2 mediates crosstalk between cancer cells and stromal fibroblasts that regulates breast cancer stem cells.
Chandra M, Zang S, Li H, Zimmerman LJ, Champer J, Tsuyada A, Chow A, Zhou W, Yu Y, Gao H, Ren X, Lin RJ, Wang SE*. Mol Cell Biol. 2012 Jun;32(12):2183-95. Nuclear translocation of type I TGF- receptor confers a novel function in RNA processing.
Wu X, Somlo G, Yu Y, Palomares MR, Li XA, Zhou W, Chow A, Yen Y, Rossi JJ, Gao H, Wang J, Yuan YC, Frankel P, Li S, Ashing-Giwa KT, Sun G, Wang Y, Smith R, Robinson K, Ren X, Wang SE*. J Transl Med. 2012 Mar;10(1):42. De novo sequencing of circulating miRNAs identifies novel markers predicting clinical outcome of locally advanced breast cancer.
Wang Y, Yu Y, Tsuyada A, Ren X, Wu X, Stubblefield K, Rankin-Gee EK, Wang SE*. Oncogene. 2011 Mar;30(12):1470-80. Transforming growth factor  regulates the sphere-initiating stem cell-like feature in breast cancer through miRNA-181 and ATM.
Yu Y, Wang Y, Ren X, Tsuyada A, Li A, Liu LJ, Wang SE*. Mol Cancer Res. 2010 Dec;8(12):1633-42. Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor  contributes to chemoresistance in breast cancer cells. Highlighted Article.
Wang SE*, Yu Y, Criswell TL, DeBusk LM, Lin PC, Zent R, Johnson DH, Ren X, Arteaga CL*. Oncogene. 2010 Jun;29(23):3335-48. Oncogenic mutations regulate tumor microenvironment through induction of growth factors and angiogenic mediators.
Wang SE*, Xiang B, Zent R, Quaranta V, Pozzi A, Arteaga CL*. Cancer Res. 2009 Jan;69(2):475-82. TGF- induces clustering of HER2 and integrins by activating Src-FAK and receptor association to the cytoskeleton.
Wang SE, Hinow P, Bryce N, Weaver AM, Estrada L, Arteaga CL, Webb GF. Comput Math Meth Med. 2009 Mar;10(1):71-83. A mathematical model quantifies proliferation and motility effects of TGF- on cancer cells.
Wang SE*, Xiang B, Guix M, Olivares MG, Parker J, Chung CH, Pandiella A, Arteaga CL*. Mol Cell Biol. 2008 Sep;28(18):5605-20. TGF- engages TACE and ErbB3 to activate PI3K/Akt in ErbB2-overexpressing breast cancer and desensitizes cells to trastuzumab.
Wang SE, Narasanna A, Whitwell CW, Wu FY, Friedman DB, Arteaga CL. J Biol Chem. 2007 Feb;282(8):5661-9. Convergence of p53 and TGF- signaling on activating expression of the tumor suppressor gene maspin in mammary epithelial cells.
Wang SE, Narasanna A, Perez-Torres M, Xiang B, Dugger TC, Wu FY, Yang S, Gazdar AF, Muthuswamy SK, Arteaga CL. Cancer Cell. 2006 Jul;10(1):25-38. HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGF receptors and resistance to EGFR tyrosine kinase inhibitors.


For more information on Dr. Wang's research, please click here